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The Yin-Yang of TNF and Type I
Interferon
Alessio Mylonas and Curdin Conrad*
Department of Dermatology, University Hospital CHUV, Lausanne, Switzerland
Chronic plaque psoriasis is a common debilitating skin disease. The identification of
the pathogenic role of the TNF/IL-23/TH17 pathway has enabled the development of
targeted therapies used in the clinic today. Particularly, TNF inhibitors have become
a benchmark for the treatment of numerous chronic inflammatory diseases such
as psoriasis. Although being highly effective in psoriasis treatment, anti-TNFs can
themselves induce psoriasis-like skin lesions, a side effect called paradoxical psoriasis.
In this review, we provide a comprehensive look at the different cellular and molecular
players involved in classical plaque psoriasis and contrast its pathogenesis to paradoxical
psoriasis, which is clinically similar but immunologically distinct. Classical psoriasis is a T-
cell mediated autoimmune disease driven by TNF, characterised by T-cells memory, and
a relapsing disease course. In contrast, paradoxical psoriasis is caused by the absence
of TNF and represents an ongoing type-I interferon-driven innate inflammation that fails
to elicit T-cell autoimmunity and lacks memory T cell-mediated relapses.
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INTRODUCTION
Psoriasis is a distinctly human, chronic, inflammatory skin disease, affecting 2–3% of the population
worldwide, with prevalence varying considerably according to race and geographic location
(1). Clinically, plaque type psoriasis, the most common form of psoriasis, is characterised
by well-demarcated erythematous lesions covered with silvery-white scales. These lesions are
histologically reflected by keratinocyte hyperproliferation leading to epidermal hyperplasia
(acanthosis), characteristic elongation of the rete ridges (papillomatosis), thickening of the
cornified layer (hyperkeratosis), and incomplete keratinocyte differentiation resulting in retention
of nuclei in the stratum corneum (parakeratosis). Leukocytes, including T-cells, dendritic cells,
neutrophils, andmacrophagesmake up a considerable dermal and epidermal immune cell infiltrate.
Psoriasis is caused by the interaction of predisposing genetic factors and environmental triggers
leading to dysregulated innate and adaptive immune responses. Today, psoriasis is widely regarded
as a T-cell-mediated autoimmune disease and skin infiltrating T lymphocytes play key effector
roles by driving disease development and maintenance. Dendritic cells producing TNF and IL-
23 stimulate activation of both CD4+ and CD8+ T-cells, which in turn migrate into the epidermis.
Upon recognition of autoantigens, T-cells produce TH17-cytokines such as IL-17A, IL-17F, and IL-
22, which drive the psoriatic phenotype by inducing keratinocyte hyperproliferation. In support of
this, several single nucleotide polymorphisms cluster throughout this pathway including genes in
the TNF/dendritic cell activation pathway (TNFAIP3, REL, TN1P1,NFKBIA) as well as in the T-cell
activation (HLA-Cw6, ERAP1/ZAP70, ETS1, SOCS1, TNFRSF9), and TH17/TC17-differentiation
pathways (IL23A, IL23R) (2, 3). Consequently, antibodies targeting the pathogenic TNF/IL-23/IL-
17 pathway have revolutionised psoriasis treatment over the past 15 years and are widely used in
the clinic today.
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In particular, TNF blockade has become the benchmark in
management of numerous chronic inflammatory diseases, such
as rheumatoid arthritis, Crohn’s disease, and psoriasis (4–7). As
such, more than two million patients have already been treated
with anti-TNFs and, with the advent of biosimilars, these figures
are expected to grow further over the coming years. Yet, targeting
TNF is not without consequence, as TNF is a potent pro-
inflammatory cytokine known to coordinate immune responses
and play an important role in limiting the spread of infectious
pathogens. Thus, TNF blockade leads to an increased risk of
infections and slightly increased risk for certain malignancies.
However, more surprisingly, anti-TNF treatment can also induce
new psoriasis-like skin lesions in about 2–5% of treated patients
(8).
As anti-TNFs are amongst the most potent anti-inflammatory
drugs used in the treatment of psoriasis, developing psoriasis-like
skin lesions due to TNF blockade was somewhat paradoxical—
hence the designation “paradoxical psoriasis.”
This review aims to provide a focussed overview of the
latest developments in the T-cell and cytokine networks in
classical psoriasis, and contrast them to paradoxical psoriasis
induced by anti-TNFs, which is clinically similar to psoriasis but
immunologically distinct. Finally, these findings will be put into
perspective with future avenues of research and possible clinical
interventions.
CLASSICAL PSORIASIS
The Established Role of T-Helper and the
Revisited Cytotoxic T-Cells
The pathogenic role for T-cells in psoriasis is well-established and
stems from the following clinical observations and experimental
findings: Immunosuppressive agents, such as cyclosporine, or
therapies specifically targeting T-cells are efficacious in psoriasis
treatment (9–12). HLA-Cw6 represents the strongest genetic
risk variant associated with psoriasis (13). Molecular analysis of
psoriasis tissue showed that lesional T-cells are oligoclonal (14)
and recognise epidermal autoantigens (15–18). Finally, clinically
relevant xenotransplant models of psoriasis have demonstrated
an essential functional role for T-cells (19–21).
T-cells migrate into inflamed skin through expression of
the skin-homing Cutaneous Lymphocyte-associated Antigen
(CLA) (22), LFA-1 and α4β1 (23), and the chemokine receptors
CCR8 and CCR10 (24). More specifically TH1 cells use CXCR3
and CCR4 (25), whereas TH17 cells use CCR4 and CCR6
(26). Among the most well-described chemokines involved
in T-cell migration to the skin are CCL27 (27, 28), and
CCL20 (29) produced by keratinocytes upon an inflammatory
trigger. While circulating T-cells certainly play an important
role in skin immunopathology, there are twice as many T-
cells residing in normal healthy skin than are present in the
circulation (22). Moreover, pathogenic oligoclonal T-cells remain
resident in resolved psoriatic skin lesions suggesting that disease
recurrence might be initiated through reactivation of skin-
resident T-cells (30). Indeed, these skin-resident memory T-
cells were found to be sufficient to drive psoriasis development
without further recruitment of circulating cells (19, 20).
Activation within the skin led to proliferation of T-cells
in the dermal compartment, which preceded keratinocyte
hyperproliferation. In fact, the psoriatic phenotype was only
induced by migration of T-cells into the epidermis and
blockade of the epidermal infiltration by T-cells prevented
the development of a psoriatic lesion (20). These findings
suggest that intraepidermal T-cells reflect key effector cells in
psoriasis.
Traditionally, much attention has been given to differentiated
CD4+ T-cell subsets across chronic inflammatory diseases (31–
34), including psoriasis (35). However, CD8+ T-cells, which are
present in healthy skin as tissue resident memory T-cells (36),
have been shown to produce a similar cytokine profile (37). In
psoriasis, dermal T-cell infiltrates are mostly comprised of CD4+
cells, whereas the majority of T-cells in the epidermis—which
represent key effector cells—are CD8+ (19). Indeed, we could
recently show that intraepidermal CD8+ T-cells are functionally
essential for psoriasis (38).
Psoriasis has been studied extensively from a genetics
perspective, with HLA class I alleles known for more than 40
years to be heavily implicated (39). The HLA-Cw6 variant is the
strongest psoriasis susceptibility allele and has 10-fold higher
association with early-onset severe psoriasis. As to how exactly
class I HLA molecules might contribute to the pathogenesis of
psoriasis is not entirely clear. But in light of the fundamental
role of epidermal CD8+ T-cells in psoriasis, the fact that
lesional T-cells are of oligoclonal origin and CD8+ T-cells
recognise peptide antigens presented on MHC class I molecules
suggest a role for epidermal (auto-)antigens in psoriasis. As
mentioned above, epidermal CD8+ T-cells in psoriasis are key
effectors in psoriasis (20), and they are of oligoclonal origin
(14, 30)—thus potentially recognising common antigens. Taken
together with HLA-Cw6 representing the strongest genetic risk
variant associated with psoriasis, this suggests that recognition
of epidermal (auto-)antigens by CD8+ T-cells is pathogenic in
psoriasis.
Indeed, the streptococcal M protein from Streptococcus
pyogenes has been identified as an antigen target of primarily
CD8+ T-cells (40). T-cells directed against the streptococcal
M-protein had the ability to react to keratin 14, which is
overexpressed in psoriatic skin, due to sequence homology and
antigenic similarity (molecular mimicry). Thus, the immune
response to a streptococcal infection could divert T-cells
toward skin antigens and cause skin pathology. Intriguingly,
streptococcal throat infections are a well-known trigger factor for
onset and exacerbation of psoriasis.
Other recently identified epidermal autoantigens include
keratin 7 (41) and the antimicrobial peptide LL37 expressed by
keratinocytes (17) as well as the melanocyte antigen ADAMTSL5
(18). Finally, CD1a-restricted lipids were also found to elicit
T-cell responses in psoriatic patients (42). Interestingly, CD1a-
autoreactive T-cells isolated from skin were identified as TH22
cells producing IL-22 (43), a cytokine overexpressed in psoriasis
and known to drive keratinocyte hyperproliferation.
Antigen-recognition by T-cells is thought to play a pivotal
role in psoriasis, but an all-encompassing consensus on the
nature of autoreactivity has yet to be reached. Despite this,
all of the identified auto-antigens to date are significantly
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upregulated in psoriatic skin as compared to uninvolved or
healthy skin. Because the majority can be induced locally
upon injury, the prevailing model postulates that skin trauma
could lead to upregulation of putative auto-antigens and their
recognition by tissue-resident antigen-experienced T-cells in
psoriasis patients.
Cytokine Networks: The TNF/IL-23/IL-17
Axis
Nowadays, the pathogenic role of the TNF/IL-23/TH17 axis
in psoriasis is well-known and numerous biologics targeting
the different cytokines of this pro-inflammatory pathway are
widely used in the clinic. Yet, the arrival of TNF blockers
in the early 2000s completely revolutionised the management
of psoriasis and other chronic inflammatory diseases. Despite
underwhelming results of anti-TNF in sepsis (44), the successful
use in rheumatoid arthritis (RA) spurred trials in other chronic
inflammatory diseases such as Crohn’s disease, psoriasis and
psoriatic arthritis (45).
TNF is known to be potently produced by immune and
non-immune cells including macrophages, T-cells, dendritic cells
(DC), neutrophils, and fibroblasts. One of its major roles is
to mount appropriate adaptive immune responses to tumors
and pathogens. This is achieved through several mechanisms.
Induction of DC-maturation leads to upregulation of CD40,
CD80, CD83, and CD86 thereby potentiating T-cell receptor
(TCR)-mediated responses and amplifying weak antigen affinity
interactions (46). It also serves to limit the immune-suppressive
effects of regulatory T-cells (47) and to enhance proliferation
and survival of committed effector memory T-cells. In line with
these findings, TNF is critically required to mount effective
CD8+ T-cell responses against tumors and for the recruitment
of T-cells into tumor sites (48). These pro-inflammatory effects
of TNF are corroborated in psoriasis, where TNF is found to
dictate the inflammatory environment in several ways (49–52).
In detailed histological andmolecular investigations, it was found
to be mostly produced by mature conventional DCs. Blockade
of TNF leads to an initial reduction of the chemokine CCL20,
which preferentially recruits TH17 cells into inflamed tissue,
coinciding with loss of IL-17 and diminution of dermal and
epidermal T-cells. In addition, it leads to normalisation of DC
numbers and reduction of IL-23 cytokine expression, followed
by normalised keratinocyte differentiation, and eventually to
histological improvement and clinical response. Taken together,
TNF maintains a pro-inflammatory environment that primes
pathogenic TH17 T-cells through induction of IL-23, maintaining
them at the site of inflammation, and sustaining TH17 cytokine
production (53, 54).
Though TNF might contribute to increased IL-17 production
by TH17 cells (55), IL-23 directly governs TH17 cytokine
production both by critically participating in TH17 cell
polarisation as well as by stimulating production of IL-17 by
differentiated TH17 cells (56, 57). Initial supportive evidence
for a functional role of IL-23 in psoriasis included the clinical
efficacy of an anti-p40 monoclonal antibody (blocking both
IL-12 and IL-23) in psoriasis (58) and the association of a
single nucleotide polymorphism in the IL23R gene in psoriasis
patients (55, 59). Confirmation soon followed by the successful
use of IL-23-specific antibodies in clinically relevant mouse
models and then in patients (60, 61). In addition, IL-4 abrogated
TH17 cell-mediated inflammation by selectively silencing IL-23
in antigen-presenting cells while sparing IL-12/TH1 immunity
(62) and resulting in therapeutic outcome. In psoriasis, IL-23
is mainly produced by activated DCs but keratinocytes and
other non-immune cells probably contribute to its production. In
fact, it has been shown recently that TNF-dependent epigenetic
control of IL-23 expression in keratinocytes plays a role in
chronic skin inflammation (63).
TH17 cytokines, such as IL-17A, IL-17F, and IL-22, represent
the key effector cytokines in psoriasis pathogenesis as they
directly drive the development of a psoriatic phenotype. They
induce epidermal hyperproliferation, attract neutrophils to the
skin, and activate keratinocytes to produce chemokines and
antimicrobial peptides, which sustain the inflammatory process
(64). There are six homologous IL-17 cytokines (A through
F) which are produced by either haematopoietic or non-
haematopoietic cells, can signal through different combinations
of receptors, and mediate distinct biological activities. The
individual members are reviewed in this issue by Brembilla et
al. (65). Besides the aforementioned effects in the pathogenesis
of psoriasis, IL-17 can act in synergy with TNF to further
potentiate expression of multiple pro-inflammatory mediators
known to play a role in psoriasis, such as IL-8, beta-defensins,
S100A proteins, IL-19, and CCL20 (29, 66–68). As such,
concurrent inhibition of TNF and IL17 might result in more
effective therapy. Though, a bi-specific dual variable domain
immunoglobulin targeting both cytokines did not demonstrate
increased efficacy compared to anti-TNF in RA (69), this remains
to be tested in psoriasis.
While antibodies targeting IL-17 have shown great efficacy
in psoriasis (53, 70), blockade of IL-22 failed to meet primary
end points in clinical trials indicating distinct role for IL-17
and IL-22 in psoriasis. IL-22, which is produced by TH17 cells
(71) and exclusively by a distinct TH22 subpopulation (72, 73),
had previously been regarded as a very promising target. In
psoriasis, IL-22 is found to be produced by dermal CD4+
but also by epidermal CD8+ TC17 and CD4
+ TH22 cells (38,
74, 75), as well as Innate Lymphoid Cells (76, 77), and mast
cells (78). Interestingly, skin-resident T-cells mediating disease
memory in clinically resolved psoriasis plaques were found to
be epidermal TC17 and TH22 cells producing mainly IL-22 (75).
Upon binding to its heterodimeric receptor consisting of IL-
22RA1 and IL10Rβ (79), which is expressed on keratinocytes
(80), IL-22 induces proliferation of keratinocytes and inhibits
terminal maturation (81, 82). While transient expression of
IL-22 upon skin injury promotes epidermal remodelling with
re-epithelisation of skin wounds (74), its chronic expression
by psoriatic T-cells drives keratinocyte hyperproliferation and
epidermal hyperplasia. In line with this, in transgenic mice, IL-22
was sufficient to induce a skin phenotype that resembles psoriasis
(82), and the psoriatic phenotype induced by skin injection
of IL-23 was abrogated in IL-22-deficient mice (83). However,
the pathogenic function of IL-22 shows redundancy with other
members of the IL-20 subfamily of cytokines such as IL-19 and
IL-20, potentially rendering its blockade clinically ineffective in
humans.
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FIGURE 1 | Pathogenesis of classical plaque psoriasis and paradoxical psoriasis. Antimicrobial peptides (AMPs), which are produced by keratinocytes upon skin
injury or released by neutrophils, form complexes with nucleic acids (NAs) released by dying cells. These complexes activate plasmacytoid dendritic cells (pDC) to
produce large amounts IFNα during the acute/early phase of psoriasis pathogenesis. IFNα activates conventional dendritic cells (cDCs), which in turn produce TNF
and IL-23. TNF induces the maturation of cDCs and pDCs, which lose their ability to produce IFNα. Thus, in classical psoriasis, early IFNα production gets relayed by
TNF that controls and limits the IFNα production by pDCs via a negative feedback loop (through induction of pDC maturation). Subsequently, IL-23 and other
pro-inflammatory cytokines produced by cDCs drive the activation of potentially autoreactive T-cells, which proliferate and, particularly CD8+ TC cells, migrate into the
epidermis. Upon antigen recognition they produce the TH17 cytokines IL-17 and IL-22 that induce keratinocyte hyperproliferation, attract neutrophils to the skin, and
upregulate AMP production providing a positive feedback loop eventually resulting in the psoriatic phenotype (chronic/late phase). Normally, during anti-TNF therapy,
the absence of TNF and consequently of downstream cytokines suppresses pathogenic T-cells thereby alleviating classical psoriasis. However, in patients developing
paradoxical psoriasis, TNF blockade inhibits pDC maturation and leads to sustained IFNα production. In addition, as cDC cannot mature in absence of TNF,
paradoxical psoriasis fails to elicit a T cell mediated autoimmune response. Thus, paradoxical psoriasis remains in an ongoing IFNα-driven acute immune inflammation
independent of T-cells. The exact pathogenic downstream mechanism of IFNα-driven paradoxical psoriasis skin lesions remains to be fully elucidated.
Detailed knowledge about the pathogenesis of chronic plaque
psoriasis and the central role for the TNF/IL-23/TH17 pathway
has led to the development of therapies targeting the pathogenic
cytokines, including anti-TNFs, anti-p40 (IL-12/IL-23), anti-p19
(IL-23 specific), anti-IL-17A, and anti-IL-17 receptor antibodies.
This pathway and its pathogenic mechanisms in classical plaque
psoriasis are illustrated in Figure 1. However, less is known about
instigators of psoriasis and pathogenic upstream triggers of acute
cutaneous inflammation.
Type I Interferons, Setting the Tone for
Autoimmunity?
Type I IFNs are key cytokines in antiviral host defence due to
their ability to limit viral replication and to induce an effective
antiviral immune response (84, 85). They promote maturation of
myeloid DCs and priming of CD8+ T-cells (86), induce T-cell
proliferation (87), and sustain their survival (88). In addition,
type-I IFNs stimulate differentiation of B-cells into antibody-
secreting plasma cells (89). Thus, type-I IFNs are essential for
the induction of an effective immune response against viruses.
Although produced by all nucleated cells, they are preferentially
expressed by a rare type of circulating cells called plasmacytoid
dendritic cells (pDCs) (90). Upon viral recognition through
endosomal Toll-like receptors (TLR) 7 and 9, pDCs produce
extraordinary amounts of type-I IFN, and, therefore, have also
been called professional IFN producing cells (90, 91). Under
normal conditions, pDCs are not present in peripheral tissues,
but they get recruited to the skin in case of infection, injury,
autoimmunity, and cancer (64). Skin wounding induces rapid
skin infiltration of pDCs and transient expression of type-I IFNs,
which accelerate re-epithelialisation (92).
As self-nucleic acids are abundantly released into the
extracellular environment during apoptotic and necrotic cell
death, it is essential that pDCs avoid inappropriate activation
by host-derived nucleic acid, but retain the ability to quickly
respond to viral DNA and RNA. To achieve this, TLRs that
sense nucleic acids are located intracellularly within endosomes,
which prevents activation by extracellular self-DNA/RNA but
allows immune response to viruses that actively invade the
cells. Moreover, extracellular nucleases rapidly degrade nucleic
acid released by dying cells without affecting DNA or RNA
contained within viruses (93). Thus, under normal circumstances
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TABLE 1 | Classical vs. Paradoxical psoriasis- differences, similarities, and treatment strategies.
Characteristics Classical psoriasis Paradoxical psoriasis
Clinico-phenotypic
presentation
Well-demarcated erythematous plaques covered with
silvery-white scales.
Presence of different psoriatic patterns including plaque-type,
guttate, pustular forms as well as eczematiform presentation.
Palmoplantar zones affected more often.
Non-cicatricial alopecia regularly noted.
Histo-pathological
appearance
Characteristic psoriatic histology: Epidermal hyperplasia
(acanthosis), papillomatosis, hyper-/parakeratosis, dermal,
and epidermal immune cell infiltrates.
Three different patterns:
-classical psoriatic pattern
-eczematiform pattern with spongiosis
-lichenoid pattern with interface dermatitis often all these
patterns are simultaneously present at variable degrees.
Recurrence Relapsing. Non-relapsing (upon cessation of anti-TNF).
Genetic associations Many known (and established): HLA-Cw6, IL12B, IL23A,
IL23R, and various components along type-I interferon
signalling, NF-KB signalling, and other signalling pathways.
Few proposed: IL23R (an allele that is protective concerning
classical psoriasis), and FBXL19, CTLA4, SCL12A8, TAPl
which have an unclear role in paradoxical psoriasis and the
outcome of the allele is undetermined.
Role of TNF Driven by TNF. Induced by blockade of TNF.
Role of adaptive immunity T-cell mediated. Intraepidermal and dermal (autoimmune)
TH/TC17-cells found throughout skin lesions.
T-cell independent. Significant reduced numbers of
intraepidermal CD8+ TC-cells as compared to classical
psoriasis.
Role of innate immunity Transiently driven by pDC derived type-I IFN during the early
phase of psoriasis development. Mature cDCs and
neutrophils present in large numbers in skin lesions of
chronic/late phase of classical psoriasis.
Driven by unabated type-I IFN produced by non-maturing
pDCs. Immature dendritic cells, and neutrophils often present
in lesions. Role for other cell types not known (particularly in
mediating the psoriatic phenotype).
Pathogenic mechanism Chronic (autoimmune) TH/TC17-mediated inflammation Unabated, ongoing type-I IFN-driven innate inflammation,
absence of T-cell autoimmunity.
Treatment avenues -targeting TNF highly effective -switch to different class of biologics (other than anti-TNF)
often needed in severe cases of paradoxical psoriasis
Various other treatment strategies validated: In the absence of detailed knowledge about the pathogenic
pathways, proposition of:
-targeting of IL-12/IL-23 highly effective
-targeting of IL-23 highly effective
-targeting IL-17A and its receptor highly effective
-targeting type-I interferon is ineffective in established
classical chronic plaque-type psoriasis.
-use of anti-IL12/IL23 (successful in case reports)
-unknown efficacy of IL-23 specific biologics
-unknown efficacy of targeting IL-17A and its receptor
-targeting type-I interferons and/or pDCs potentially effective
host-derived self-DNA/RNA released by apoptotic or damaged
cells cannot activate TLR9 and 7. However, they can become
potent triggers of pDC activation and type-I IFN production
in the presence of endogenous antimicrobial peptides (AMP)
such as LL37 and beta-defensins (94–96). AMPs are typically not
expressed in healthy skin under steady-state conditions, but are
transiently produced by keratinocytes or released by infiltrating
neutrophils in response to skin wounding or infections (97–
99). Their cationic and amphipathic structure allows AMPs to
interact with and disrupt microbial membranes, which typically
contain a high degree of negative charges (100). Besides their
role as direct effector molecules against microorganisms, AMPs
are also involved in the initiation of inflammation by breaking
innate tolerance to otherwise inert extracellular self-DNA and
self-RNA. Cationic AMPs bind to negatively charged fragments
of nucleic acid to form aggregated and condensed structures that
are resistant to extracellular degradation. Translocation of these
complexes into endosomes and activation of TLR7 and 8 (RNA),
or TLR9 (DNA) lead to sustained production of IFNα and IFNβ
by pDCs (94–96).
Under physiological conditions, AMP-expression with
activation of pDCs by AMP-nucleic acid complexes is transient,
controlled by the damaging or infectious stimulus. By contrast,
in psoriasis, the expression of AMPs is persistent and leads
to sustained production of type-I IFNs by pDCs, which
accumulate in the dermis of early developing psoriatic lesions
(101). Subsequently, these trigger activation of myeloid DCs
and autoreactive T-cells. Recent work has demonstrated that
IFNα particularly drives the activation and skin infiltration
of pathogenic CD8+ T-cells in psoriasis (102). Moreover,
IFNα conditioned DCs produce large amounts of IL-23
(103, 104) indicating an important role for type-I IFNs in
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driving TH/TC17-mediated (auto)immunity in psoriasis.
Indeed, depletion of pDCs or blocking type-I IFN signalling
both inhibited psoriasis development confirming that its
overexpression by pDCs reflects a critical early/acute event in the
pathogenesis of psoriasis (101). This is further supported by the
observations that de novo psoriasis or pre-existing psoriasis can
be triggered and/or aggravated by IFNα therapy (105–108) and
the TLR7 agonist imiquimod (109, 110). Interestingly, epidermal
trauma, which induces AMP expression by keratinocytes and
attracts pDCs into the skin, is also a typical trigger of psoriasis
known as Koebner phenomenon.
Taken together, type-I IFNs play a critical role in the
acute/early phase of psoriasis pathogenesis by (1) activating
dermal myeloid DC, (2) inducing their maturation by
upregulating co-stimulatory molecules and HLA molecules,
and (3) participating in TH/TC17 polarisation of autoimmune
T-cells through induction of IL-23 production by myeloid DCs
(Figure 1).
PARADOXICAL PSORIASIS
Almost two decades of clinical experience with anti-TNFs have
provided considerable advances in our understanding of the
biology of TNF. More than 2 million patients have been treated
with anti-TNFs so far.
Expected side effects such as increased susceptibility to
infection and a slightly increased risk for malignancies have
been confirmed (111–113), though the cancer risk still remains
a matter of debate (114, 115). However, the observation that anti-
TNFs, which are normally extremely effective in the treatment of
chronic inflammatory diseases, could lead to aggravation of pre-
existing autoimmune diseases and onset of new inflammatory
diseases, was unexpected and a paradox. In fact, lupus-like
syndrome can be observed in 0.5–1% of anti-TNF treated patients
and 2–5% of patients develop psoriasis-like skin lesions, called
paradoxical psoriasis (8, 116, 117). They represent important side
effects in the treatment of major chronic autoimmune diseases
as they potentially necessitate treatment cessation. Since the first
description of paradoxical psoriasis (117, 118), numerous cases
have been reported (119–121). Paradoxical psoriasis appears
independently of the underlying disease or the type of anti-
TNF agent used and regresses upon discontinuation of therapy,
which suggests that paradoxical psoriasis does represent a side
effect of TNF blockade and not de novo psoriasis. Though the
side effect is a well-established phenomenon, its pathogenesis
had remained elusive and only recently, the dysbalance of
TNF and type-I IFN (yin-yang of TNF and IFNα) has been
confirmed as a pathogenic mechanism underlying paradoxical
psoriasis (8).
The first clues for a link between anti-TNF therapy and
increased type-I IFN expression came from the observation
that anti-TNF therapy induces an IFN signature in blood of
juvenile arthritis patients (122). Likewise, anti-TNF treatments
promote formation of anti-nuclear antibodies (123), which are
associated with increased type-I IFN levels in SLE patients
(124). Furthermore, anti-TNFs can induce or aggravate lupus, a
well-known type-I IFN-driven autoimmune disease (125, 126).
Indeed, patients with anti-TNF induced paradoxical psoriasis
showed an increased IFN signature in lesional skin (127).
Recently, we could confirm that TNF controls the production
of type I-IFN by pDCs and that anti-TNF induces its unabated
overexpression driving paradoxical psoriasis (8).
Upon activation, pDCs produce type-I IFNs first, which is
relayed by their production of TNF. TNF induces maturation of
pDCs, which upregulate costimulatory molecules and lose their
ability to produce interferons (8, 128). Thereby, TNF limits the
duration of type-I IFN production by pDCs, while conversely,
TNF blockade decreases pDC maturation and extends their
ability to produce type-I IFN. This supports a yin-yang model
of TNF and type-I IFN. In classical plaque psoriasis, early
transient overexpression of type-I IFN is replaced by a dominant
TNF-driven chronic inflammation. In contrast, TNF blockade
leads to an ongoing type-I IFN mediated acute inflammation in
paradoxical psoriasis (Figure 1).
Another important distinction between the two entities is
that in paradoxical psoriasis, unlike classical psoriasis, T-cells
play a redundant role (8). Hence, both classical and paradoxical
psoriasis are induced by pDC-derived type-I IFN. But while
classical psoriasis develops into a T-cell mediated autoimmune
disease, paradoxical psoriasis represents an ongoing type-I
IFN-driven innate immune response that fails to elicit T cell
autoimmunity. In line with this, there are no relapses of
paradoxical psoriasis upon discontinuation of anti-TNF therapy,
which supports lack of T-cell mediated disease memory in
paradoxical psoriasis.
It remains unclear what triggers the activation of pDCs
and eventually drives paradoxical psoriasis. Potentially
certain environmental factors such as microbes could trigger
development of paradoxical psoriasis, as a considerable number
of patients have been found to have concurrent superinfections
(129). Furthermore, the yin-yang of TNF and type-I IFN, the
pathogenic mechanism underlying paradoxical psoriasis, is
inherently true for healthy individuals as much as patients. But
only 2–5% of anti-TNF treated patients develop paradoxical
psoriasis indicating that there is another key determining
factor such as genetic predisposition for paradoxical psoriasis.
Among polymorphisms associated with psoriasis, five have been
identified to also be associated to paradoxical psoriasis, and
these include IL23R, FBXL19, CTLA4, SLC12A8, and TAP1 (130)
though it remains to be determined exactly how they would fit in
the pathological mechanism.
Though classical and paradoxical psoriasis have similarities
in their clinical presentation, many distinctions have been
identified in recent years as to the pathogenic mechanism.
Table 1 summarises key similarities and differences between the
two entities, and highlights potential treatment strategies.
OUTLOOK
Detailed knowledge on classical plaque psoriasis, particularly by
identifying the relevant role of the TNF/IL-23/TH17 axis in its
pathogenesis, has allowed for novel, more targeted therapies.
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Though newer treatments targeting IL-23 and IL-17 show
better efficacy, today, anti-TNFs remain a gold-standard in
psoriasis management. Yet important immunological side effects
of TNF blockade, such as paradoxical psoriasis and lupus-
like syndrome, may require premature discontinuation of an
otherwise effective treatment option for patients. These side
effects are caused by an unabated type-I IFN-driven immune
response making it an intriguing target in these patients.
While, anti-IFNs have not shown efficacy in chronic plaque
psoriasis confirming the distinct inflammatory pathways in
chronic and acute forms of classical psoriasis (131), they provided
promising results in SLE. Therefore, type-I IFN blockade might
be a valuable treatment option in acute forms of psoriasis
such as erythrodermic or guttate psoriasis as well as in
paradoxical psoriasis. However, simultaneous inhibition of the
interferon pathway together with the ongoing TNF blockade
might increase the infectious risk too considerably. Therefore,
targeting IFN-producing pDCs (i.e., via anti-ILT-7, anti-BDCA2)
or inhibiting TLR 7 and 9, thereby blocking pDC activation,
could provide more suitable therapeutic options in patients that
need continuation of their anti-TNF treatment. In this way,
production of type-I IFNs by monocytes and stromal cells would
remain intact and might allow sufficient immune responses
toward infectious agents.
Despite considerable advances in the understanding of
paradoxical psoriasis and its pathogenesis, several questions
are still unanswered. Downstream mechanisms that mediate
the interferon-driven psoriatic phenotype of paradoxical
psoriasis remain unknown as IFNα does not directly
induce keratinocyte hyperproliferation. The identification
of cytokines involved and their cellular source might provide
additional novel targets for therapeutic intervention. In
addition, biomarkers to predict side effects such as paradoxical
psoriasis and lupus-like syndrome could help optimising
the management of patients with chronic inflammatory
diseases.
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